$-0.83 EPS Expected for Caladrius Biosciences, Inc. (CLBS)

February 24, 2018 - By marketbeat

 $ 0.83 EPS Expected for Caladrius Biosciences, Inc. (CLBS)

Analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS) to report $-0.83 EPS on March, 16.They anticipate $0.10 EPS change or 13.70 % from last quarter’s $-0.73 EPS. After having $-0.38 EPS previously, Caladrius Biosciences, Inc.’s analysts see 118.42 % EPS growth. The stock 0.10% or $0 during the last trading session, reaching $4.26. It is down 9.24% since February 24, 2017 and is downtrending. It has underperformed by 25.94% the S&P500.

Caladrius Biosciences, Inc. (NASDAQ:CLBS) Ratings Coverage

Among 4 analysts covering Caladrius Biosciences (NASDAQ:CLBS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Caladrius Biosciences had 12 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Caladrius Biosciences, Inc. (NASDAQ:CLBS) earned “Buy” rating by Chardan Capital Markets on Tuesday, August 23. The stock has “Buy” rating by H.C. Wainwright on Friday, August 11. H.C. Wainwright maintained it with “Buy” rating and $7.0 target in Wednesday, September 6 report. The firm earned “Hold” rating on Friday, January 8 by Benchmark. Benchmark downgraded Caladrius Biosciences, Inc. (NASDAQ:CLBS) on Friday, August 7 to “” rating. The stock has “Buy” rating by H.C. Wainwright on Friday, November 10. On Friday, July 21 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was downgraded by Maxim Group on Thursday, January 7 to “Hold”. The rating was upgraded by H.C. Wainwright on Friday, April 29 to “Buy”. The rating was downgraded by H.C. Wainwright to “Neutral” on Friday, January 8.

More notable recent Caladrius Biosciences, Inc. (NASDAQ:CLBS) news were published by: Marketwatch.com which released: “Caladrius Biosciences Inc.” on January 10, 2016, also Quotes.Wsj.com with their article: “News Caladrius Biosciences Inc.CLBS” published on June 09, 2015, Seekingalpha.com published: “The Strange Case Of Caladrius Biosciences” on April 17, 2017. More interesting news about Caladrius Biosciences, Inc. (NASDAQ:CLBS) were released by: Globenewswire.com and their article: “Caladrius Biosciences Awarded Approximately $2 Million NIH Grant to Support …” published on October 02, 2017 as well as Seekingalpha.com‘s news article titled: “Is Caladrius Biosciences Inc. A Buy?” with publication date: March 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: